The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis.

Karadag-Saygi, NAİME; Akyuz, GÜLSEREN; Bizargity, Peyman; Ay, NADİYE

doi:10.3109/09513590.2011.579657

The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis.

Karadag-Saygi E., Akyuz G., Bizargity P., Ay P.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, cilt.27, sa.12, ss.1033-6, 2011 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 27 Sayı: 12
Basım Tarihi: 2011
Doi Numarası: 10.3109/09513590.2011.579657
Dergi Adı: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1033-6
Anahtar Kelimeler: Osteoporosis, risedronate, osteoprotegerin, bone marker, SOLUBLE RECEPTOR ACTIVATOR, FACTOR-KAPPA-B, DISEASE-ACTIVITY, MINERAL DENSITY, PAGETS-DISEASE, LIGAND, TURNOVER, FRACTURES, THERAPY, MASS
Marmara Üniversitesi Adresli: Evet

Özet

Background. To evaluate the effect of risedronate treatment on osteoprotegerin (OPG), C-terminal cross-linking telopeptide of type 1 collagen (CTX), osteocalcin (OC), and deoxypyridinoline (DPD).